A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g
This study has been completed.
First Posted: November 15, 2004
Last Update Posted: March 20, 2014
Information provided by (Responsible Party):
This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.
|Study Design:||Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||An Open Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g|
Resource links provided by NLM:
Further study details as provided by Genentech, Inc.:
Contacts and Locations
No Contacts or Locations Provided